DGAP-News: STADA sales companies achieve very good results in the 8th AOK tender round in the German generics market
(firmenpresse) - DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous
STADA sales companies achieve very good results in the 8th AOK tender
round in the German generics market
23.05.2012 / 11:22
---------------------------------------------------------------------
Bad Vilbel, May 23, 2012 - In the view of the STADA Executive Board, STADA
sales companies STADApharm GmbH, ALIUD PHARMA GmbH and cell pharm
Gesellschaft für pharmazeutische und diagnostische Präparate mbH achieved
very good results in the 8th round of German-wide tenders of the
Allgemeinen Ortskrankenkassen (AOK) for pharmaceutical discount agreements
pursuant to Section 130 a SGB V.
As part of this most recent AOK round with a total tender volume of approx.
EUR 360 million, the three STADA sales companies concluded contracts for a
total of five active pharmaceutical ingredients with the AOK which, with
about one-third of all publicly insured persons in Germany, is the largest
German health insurance organization.
For the individual active ingredients, between one and eight regional lots
were awarded. Of the active ingredients awarded in total, two were
accounted for by STADApharm, one by ALIUD PHARMA and one by cell pharm. One
active ingredient is shared by STADApharm and ALIUD PHARMA. Here,
STADApharm was awarded three regional lots, and ALIUD PHARMA was awarded
five regional lots.
The contracts are legally effective and take effect on October 1, 2012. The
regular term has been set at two years. Depending on the active ingredient,
the STADA sales companies received the award for three to eight regional
lots. With the award for eight regional lots, the respective STADA sales
company is the sole contract partner of the AOK (single source).
In light of these newly concluded discount agreements with the AOK and the
recently received awards of discount agreement on a multi-source basis,
among other things in the last tender rounds of the GWQ 5 and KKH 5, the
STADA Executive Board continues to expect that the Group's market share by
volume in the German market will increase further. Recently, STADA's market
share by volume in the first quarter of 2012 grew from 12.4% in the
corresponding period of the previous year to approx. 13.4%.
Additional information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D -
61118 Bad Vilbel /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-Mail:
communications(at)stada.de /
Or visit us in the Internet at www.stada.com.
End of Corporate News
---------------------------------------------------------------------
23.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications(at)stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
171117 23.05.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.05.2012 - 11:22 Uhr
Sprache: Deutsch
News-ID 149157
Anzahl Zeichen: 4748
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 356 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STADA sales companies achieve very good results in the 8th AOK tender round in the German generics market"
steht unter der journalistisch-redaktionellen Verantwortung von
STADA Arzneimittel AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
